LIQUICHEK ANA CONTROL, NUCLEOLAR PATTERN, POSITIVE, CATALOG #111

K024229 · Bio-Rad · DHN · Jan 15, 2003 · Immunology

Device Facts

• Record ID: K024229
• Device Name: LIQUICHEK ANA CONTROL, NUCLEOLAR PATTERN, POSITIVE, CATALOG #111
• Applicant: Bio-Rad
• Product Code: DHN · Immunology
• Decision Date: Jan 15, 2003
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 866.5100
• Device Class: Class 2

Intended Use

The Liquichek™ ANA Control, Nucleolar Pattern, Positive, is intended for use as an unassayed quality control to monitor indirect immunofluorescent testing of antinuclear antibodies (ANA).

Device Story

Liquichek™ ANA Control, Nucleolar Pattern, Positive is a liquid, human serum-based quality control material. It is used in clinical laboratories to monitor the performance of indirect immunofluorescent (IIF) assays for antinuclear antibodies. The control provides a standardized nucleolar pattern for verifying assay consistency and accuracy. Laboratory personnel use the control alongside patient samples during routine testing. By comparing the observed immunofluorescent pattern and intensity of the control against expected results, clinicians can validate the reliability of the testing process. This helps ensure accurate identification of autoantibodies, supporting the diagnosis and management of autoimmune conditions.

Clinical Evidence

Bench testing only. Stability studies confirmed an open-vial stability of 60 days when stored at 2-8°C and a shelf life of 2 years when stored unopened at 2-8°C.

Technological Characteristics

Human serum-based liquid control with added preservatives. Designed for 2-8°C storage. No specific sensing or energy source; functions as a biological reference material for immunofluorescence microscopy.

Indications for Use

Indicated for use as an unassayed quality control to monitor indirect immunofluorescent testing of antinuclear antibodies (ANA) in clinical laboratory settings.

Regulatory Classification

Identification

An antinuclear antibody immunological test system is a device that consists of the reagents used to measure by immunochemical techniques the autoimmune antibodies in serum, other body fluids, and tissues that react with cellular nuclear constituents (molecules present in the nucleus of a cell, such as ribonucleic acid, deoxyribonucleic acid, or nuclear proteins). The measurements aid in the diagnosis of systemic lupus erythematosus (a multisystem autoimmune disease in which antibodies attack the victim's own tissues), hepatitis (a liver disease), rheumatoid arthritis, Sjögren's syndrome (arthritis with inflammation of the eye, eyelid, and salivary glands), and systemic sclerosis (chronic hardening and shrinking of many body tissues).

Predicate Devices

• Kallestad™ Autoantibody Positive Control (K792610)

Submission Summary (Full Text)

{0}------------------------------------------------

KO24229

# Summary of Safety and Effectiveness Liquichek™ ANA Control Nucleolar Pattern, Positive

#### 1.0 Submitter

JAN 1 5 2003

Bio-Rad Laboratories 9500 Jeronimo Road, Irvine, California 92618-2017 Telephone: [phone] Fax: [phone]

## Contact Person

Yvette Lloyd Senior Regulatory Affairs Specialist Telephone: [phone]

# Date of Summary Preparation

December 20, 2002

#### 2.0 Device Identification

| Product Trade Name: | Liquichek™ ANA Control Nucleolar Pattern, Positive |
|---------------------|-----------------------------------------------------------------------|
| Common Name: | Antinuclear Antibody, Indirect Immunofluorescent,<br>Antigen, Control |
| Classifications: | Class II |
| Product Code: | 82DHN |
| Regulation Number: | 21 CFR 866.5100 |

### 3.0 Device to Which Substantial Equivalence is Claimed

Kallestad™ Autoantibody Positive Control Bio-Rad Laboratories

510 (k) Number: K792610

#### 4.0 Description of Device

This product is prepared from human serum with added preservatives. The control is provided in liquid form for convenience.

{1}------------------------------------------------

#### Statement of Intended Use 5.0

The new Liquichek™ ANA Control, Nucleolar Pattern, Positive, is intended for use as an unassayed quality control to monitor indirect immunofluorescent testing of antinuclear antibodies (ANA).

#### Comparison of the new device with the Predicate Device 6.0

This control is substantially equivalent to the following quality control material for autoimmune analysis that is currently in the market:

Kallestad™ Autoantibody Positive Control Bio-Rad Laboratories

510 (k) Number: K792610

Table 1. Similarities and Differences between new and predicate device.

| Characteristics | Liquichek™ ANA Control,<br>Nucleolar Pattern, Positive<br>(New Device) | Kallestad™ Autoantibody Positive<br>Control<br>(Predicate Device) |
|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Similarities | | |
| Intended Use | The Liquichek™ ANA Control,<br>Nucleolar Pattern, Positive, is<br>intended for use as an unassayed<br>quality control to monitor indirect<br>immunofluorescent testing of<br>antinuclear antibodies (ANA). | The Autoantibody Positive Control<br>is a replacement reagent in the<br>Kallestad Fluorescent<br>Autoantibody test with mouse<br>kidney, mouse stomach/kidney,<br>Hep-2 cell line, or Crithidia luciliae<br>substrates. |
| Matrix | Human Serum | Human Serum |
| Storage<br>(Unopened) | 2°C to 8°C<br>until expiration date | 2°C to 8°C<br>until expiration date |
| Form | Liquid | Liquid |

{2}------------------------------------------------

| Differences | | |
|-----------------------|-----------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|
| Stability<br>(Opened) | Once opened the analyte will be stable for 60 days. | No claim for stability |
| Analyte | ANA Nucleolar Pattern | ANA: Centromere Pattern, SSA, SSB, Scl-70, Sm, RNP, Spindle Pattern, Nucleolar Pattern<br>AMA<br>ASMA<br>APCA<br>Anti-nDNA |

#### 7.0 Summary of Performance Data

Stability studies have been performed to determine the open vial stability and shelf life for the Liquichek™ ANA Control, Nucleolar Pattern, Positive. Product claims are as follows:

- 7.1 Once the control is opened the analyte will be stable for 60 days when stored tightly capped at 2 to 8°C.
- 7.2 The control is stable for 2 years when stored unopened at 2 8°C.

Real time studies will be ongoing to support the shelf life of this product.

All supporting data is retained on file at Bio-Rad Laboratories.

{3}------------------------------------------------

Image /page/3/Picture/1 description: The image shows the logo for the Department of Health & Human Services - USA. The logo is a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" written around the perimeter. Inside the circle is an abstract image of a human figure with three lines extending from the head.

Food and Drug Administration 2098 Gaither Road Rockville MD 20850

JAN 1 5 2003

Ms. Yvette Lloyd Senior Regulatory Affairs Specialist Bio-Rad Laboratories, OSD 9500 Jeronimo Road Irvine, CA 92618-2017

> k024229 Trade/Device Name: Liquichek 114 ANA Control. Nucleolar Pattern, Positive Regulation Number: 21 CFR 866.5100 Regulation Name: Antinuclear antibody immunological test system Regulatory Class: Class II Product Code: DHN Dated: December 20, 2002 Received: December 23, 2002

Dear Ms. Lloyd:

Re:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the A.ct. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21. Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

{4}------------------------------------------------

## Page 2 –

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at [phone]. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number [phone] or [phone] or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.

Sincerely yours,

iteven Sutman

Steven I. Gutman, M.D., M.B.A. Director Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health

Enclosure

{5}------------------------------------------------

510 (k) Number (if known): K034229

Device Name: Liquichek™ ANA Control, Nucleolar Pattern, Positive

Indications for Use:

The Liquichek™ ANA Control, Nucleolar Pattern, Positive, is intended for use as an unassayed quality control to monitor indirect immunofluorescent testing of antinuclear antibodies (ANA).

(PLEASE DO NOT WRITE BELOW THE LINE-CONINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

V Prescription use or

Over-the Counter use

A. Reeves for J. Bautista

(Division Sign-Off) Division of Clinical Labora 510(k) Number -